Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent
NCT02189499 is a phase 2 interventional trial sponsored by Amaranth Medical Inc.. As of 21 Nov 2026, it has a status the registry marks as unknown. It studies Coronary Artery Disease and Myocardial Ischemia. The registry lists an enrollment of 42 participants at 4 sites in 1 country. The registry lists a start date of 30 Sept 2014 and a primary completion date of 30 Jun 2016.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT02189499 |
| Status | Unknown |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | Amaranth Medical Inc. |
| Enrollment | 42 |
| Registered sites | 4 |
| Countries | 1 |
| Conditions | Coronary Artery Disease and Myocardial Ischemia |
| Start | 30 Sept 2014 |
| Primary completion | 30 Jun 2016 |
| Study completion | 30 Nov 2020 |
| Last update posted | 8 Jun 2016 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Juan F Granada, MD
Skirball Center for Cardiovascular Research, Columbia University Medical Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Clinica de Marly
Bogotá
- Instituto del Corazon
Bucaramanga
- Angiografia de Occidente S.A.
Cali
- Emmsa Clinica Especializada
Medellín
Sites by country
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Questions about NCT02189499
Each answer restates registry values shown on this page.
What is NCT02189499?
NCT02189499 is a phase 2 interventional trial sponsored by Amaranth Medical Inc.. It studies Coronary Artery Disease and Myocardial Ischemia.
Who leads NCT02189499?
The registry names Juan F Granada, MD (principal investigator, Skirball Center for Cardiovascular Research, Columbia University Medical Center) as the overall official.
Where does NCT02189499 run?
The registry lists 4 sites in 1 country. Every site with a stated country is in one country: Colombia.
When is NCT02189499 expected to complete?
The registry lists a primary completion date of 30 Jun 2016 and a study completion date of 30 Nov 2020. The sponsor last updated the record on 8 Jun 2016.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.